

Efficacy of Weekly Docetaxel and Bevacizumab in Mesenchymal Chondrosarcoma: a New Theranostic Method Combining Xenografted Biopsies with a Mathematical Model

Gorelik B.¹, Ziv I.¹, Shohat R.¹, Wick M.², Hankins D.^{4,5}, Sidransky D.^{5,*}, Agur Z.^{1,6,*}

¹Optimata Ltd., Ramat-Gan 52522, Israel; ²CTRC Institute for Drug Development, San Antonio, TX, USA;; ⁴New Hope Pharmaceuticals Inc., Bethesda, MD, USA; ⁵John Hopkins University School of Medicine, Baltimore, MD, USA; ⁶Institute for Medical BioMathematics (IMBM), Bene Ataroth, Israel.
*Co-Senior Author.

Supplementary material




Figure S1 Schematic workflow of the study design

Table S1 Sources for PK data. The numbers refer to the sources listed as "References" of this supplementary material

<u>Drug</u>	<u>Mice</u>	<u>Human</u>
Docetaxel	S1	S2,S3
Doxorubicin	S4	S5
Gemcitabine	S6, S7, S8	S9, S10
Irinotecan	S11	S12
Bevacizumab	S10	S13
Sorafenib	S14	S15

Table S2 Sources for PD data. The numbers refer to the sources listed as "References" of this supplementary material

<u>Drug</u>	<u>Reference number</u>
Bevacizumab	S16, S17
Sorafenib	S18

References

- S1. Shimada T, Nomura M, Yokogawa K, et al. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. *J Pharm Pharmacol*. 2005;57:177-181.
- S2. Van Zuylen L, Sparreboom A, van der GaA, et al. Disposition of Docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. *Eur J Cancer*. 2002;38:1090-1099.
- S3. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. *Cancer Res*. 1993;53:1037-1042.
- S4. Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. *Cancer Chemother Pharmacol*. 1981;5:267-270.
- S5. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. *J Clin Oncol*. 1997;15:1906-1915.
- S6. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. *Drug Metab Dispos*. 1992;20:849-855.
- S7. Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. *Clin Cancer Res*. 2004;10:1633-1644.
- S8. van Moorsel CJ, Pinedo HM, Smid K, et al. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours. *Eur J Cancer*. 2000;36:2420-2429.
- S9. Shamseddine AI, Khalifeh MJ, Mourad FH, et al. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. *Clin Pharmacokinet*. 2005;44:957-967.
- S10. Lin NM, Zeng S, Ma SL, Fan Y, Zhong HJ, Fang L. Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector. *Acta Pharmacol Sin*. 2004;25:1584-1589.

- S11. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. *Cancer Chemother Pharmacol.* 1998;42:165-170.
- S12. Masi G, Falcone A, Di Paolo A, et al. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. *Clin Cancer Res.* 2004;10:1657-1663.
- S13. European Medicines Agency. Avastin, INN-bevacizumab. 2005.
- S14. Center for drug evaluation and research, FDA. Approval package for application number NDA 21-923. 2005.
- S15. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. *Cancer Chemother Pharmacol.* 2006;57:685-692.
- S16. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. *J Biol Chem.* 2006;281:951-961.
- S17. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. *Am J Pathol.* 1998;153:1249-1256.
- S18. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res.* 2004;64:7099-7109.